市场调查报告书
商品编码
1403327
静脉血栓栓塞治疗市场:按设备、库存、应用、最终用户划分 - 全球预测(~2030 年)Venous Thromboembolism Treatment Market by Device (Thrombectomy, Inferior Vena Cava Filter [Retrievable, Permanent], Stockings, Compression Pump) Application (DVT, Pulmonary Embolism) End User (Hospital, Ambulatory Care Center) - Global Forecast to 2030 |
预计2030年全球静脉血栓栓塞治疗市场规模将达44亿美元,2023年至2030年复合年增长率为7.2%。
在对市场状况进行广泛的初级和二级研究以及深入分析后,本报告深入了解静脉血栓栓塞治疗市场的关键驱动因素、限制、挑战和机会。
静脉血栓栓塞的高发生率、癌症发生率的上升、糖尿病和肥胖等继发性危险因子的盛行率不断增加、骨科手术数量的增加以及对微创治疗手术的需求不断增加,是推动静脉血栓成长的关键因素。血栓栓塞治疗市场。此外,治疗方案的可用性和可负担性的提高、VTE诊断和治疗方法的进步以及新兴国家的市场扩张预计将为市场成长创造机会。
然而,产品缺陷和产品召回的情况可能会抑制市场成长。此外,缺乏对静脉血栓栓塞的认识以及对压缩衣副作用的认识不断增强是市场成长的主要挑战。
在本报告涵盖的设备中,血栓切除设备预计将在 2023 年占据静脉血栓栓塞治疗市场的最大份额。该细分市场的巨大市场份额是由于心血管疾病的盛行率不断上升、对微创手术的日益偏好以及新型血栓切除设备的推出。
在本报告涵盖的应用中,深部静脉血栓领域预计将在2023年占据静脉血栓栓塞治疗市场的最大份额。此细分市场的巨大市场份额是由于肥胖症盛行率不断上升、老年人口不断增加、生活方式相关疾病导致的深部静脉栓塞病例不断增加、过度饮酒以及对 DVT 的认识不断提高。
在本报告涵盖的最终用户中,医院部门预计将在 2023 年占据静脉血栓栓塞治疗市场的最大份额。这一巨大的市场份额归因于静脉血栓栓塞的盛行率不断上升、医院和诊所数量不断增加、高技能专业人员的存在以及医院的高购买力。前往医院的便利性以及大量患者在同一地点寻求全面医疗保健服务(包括诊断、治疗和手术)也有助于该细分市场占据巨大的市场份额。
全球静脉血栓栓塞治疗市场区域状况的详细分析为五个关键区域提供了详细的定性和定量见解:北美(美国、加拿大)、欧洲(德国、法国、亚太地区(中国、日本、印度)、拉丁美洲以及中东/非洲其他地区。
预计到2023年,北美将占据全球静脉血栓栓塞治疗市场的最大份额,其次是欧洲、亚太地区、拉丁美洲以及中东和非洲。然而,亚太地区预计在预测期内复合年增长率最高。该区域市场的成长是由慢性病盛行率上升、久坐生活方式的人数增加、医疗保健成本增加、政府旨在改善医疗基础设施的支持措施以及静脉血栓栓塞等因素所推动的。这被认为是由于以下因素造成的例如提高对该问题的认识。
Venous Thromboembolism Treatment Market by Device (Thrombectomy, Inferior Vena Cava Filter [Retrievable, Permanent], Stockings, Compression Pump) Application (DVT, Pulmonary Embolism) End User (Hospital, Ambulatory Care Center) - Global Forecast to 2030.
The global venous thromboembolism treatment market is projected to reach $4.40 billion by 2030, at a CAGR of 7.2% from 2023 to 2030.
After conducting an extensive primary and secondary study and an in-depth analysis of the market scenario, this report offers insights into the key drivers, constraints, challenges, and opportunities within the venous thromboembolism treatment market.
The high prevalence of venous thromboembolism, rising incidence of cancer, growing prevalence of secondary risk factors such as diabetes and obesity, increase in orthopedic surgical procedures, and the rising demand for minimally invasive treatment procedures are the key factors driving the growth of the venous thromboembolism treatment market. Furthermore, the growing accessibility and affordability of treatment options, advancements in VTE diagnosis and treatment methods, and the market expansion in emerging economies are expected to create market growth opportunities.
However, instances of product failure and product recalls may restrain the market's growth. Additionally, lack of awareness about venous thromboembolism and increasing awareness of probable side effects of compression garments are major challenges for market growth.
Among the devices covered in this report, in 2023, the thrombectomy devices segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share of this segment is attributed to the increasing prevalence of cardiovascular diseases, growing preference for minimally invasive procedures, and launches of new thrombectomy devices.
Among the applications covered in this report, in 2023, the deep vein thrombosis segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share of this segment is attributed to the increasing prevalence of obesity, a growing geriatric population, rising cases of deep vein thrombosis due to lifestyle-related diseases, excessive alcohol consumption, and heightened awareness of DVT.
Among the end users covered in this report, in 2023, the hospitals segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share is attributed to the increasing prevalence of venous thromboembolism, the rising number of hospitals and clinics, the presence of highly skilled professionals, and the high purchasing power of hospitals. The easy accessibility to hospitals, coupled with a large patient population seeking comprehensive healthcare services, including diagnosis, treatment, and surgeries at a single location, also contributes to the significant market share of this segment.
An in-depth analysis of the geographical scenario of the global venous thromboembolism treatment market provides detailed qualitative and quantitative insights into the five major geographies: North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India), Latin America, and the Middle East & Africa.
In 2023, North America is expected to account for the largest share of the global venous thromboembolism treatment market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. However, Asia-Pacific is slated to register the largest CAGR during the forecast period. The growth of this regional market can be attributed to factors such as the growing prevalence of chronic diseases, the increasing number of people living sedentary lifestyles, growing health expenditures, supportive government initiatives aimed at improving healthcare infrastructure, and rising awareness regarding venous thromboembolism.
The key players operating in the global venous thromboembolism treatment market are ALN Implants chirurgicaux (ALN Surgical Implants) (France), AngioDynamics, Inc. (U.S.), Argon Medical Devices, Inc. (U.S.), ArjoHuntleigh AB (Sweden), Boston Scientific Corporation (U.S.), Cardinal Health, Inc. (U.S.), Cook Group Incorporated (U.S.), Koninklijke Philips N.V. (Netherlands), DS MAREF Co., LTD (South Korea), Enovis Corporation (U.S.), LifeTech Scientific Corporation (China), Medtronic plc (Ireland), and Stryker Corporation (U.S.).
Venous Thromboembolism Treatment Market Assessment-by Device
Note: Other devices & accessories include extraction and repositioning devices for vena cava filters and garments for compression therapy (excluding stockings).
Venous Thromboembolism Treatment Market Assessment-by Application
Venous Thromboembolism Treatment Market Assessment-by End User
Note: Other end users include nursing care centers, long-term care centers, and military health centers.
Venous Thromboembolism Treatment Market Assessment-by Geography